| 3.37 0.13 (4.01%) | 10-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.92 |
1-year : | 5.79 |
| Resists | First : | 4.21 |
Second : | 4.96 |
| Pivot price | 3.9  |
|||
| Supports | First : | 3 |
Second : | 2.5 |
| MAs | MA(5) : | 3.84 |
MA(20) : | 3.76 |
| MA(100) : | 3.03 |
MA(250) : | 2.99 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 36.7 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 4.96 | Low : | 1.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACST ] has closed above bottom band by 44.0%. Bollinger Bands are 86.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.18 - 4.2 | 4.2 - 4.21 |
| Low: | 3.78 - 3.81 | 3.81 - 3.82 |
| Close: | 3.8 - 3.83 | 3.83 - 3.86 |
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Tue, 07 Jan 2025
Acasti Pharma (TSXV:ACST) PS Ratio : (As of Jan. 07, 2025) - GuruFocus.com
Tue, 07 Jan 2025
Grace Therapeutics to Participate in Upcoming Investor Events January 2025 - The Manila Times
Fri, 25 Oct 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire
Fri, 25 Oct 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - StockTitan
Fri, 14 Jul 2023
Best Pharmaceutical Penny Stocks to Buy Now - Investment U
Mon, 10 Jul 2023
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 38.3 (%) |
| Held by Institutions | 21.2 (%) |
| Shares Short | 154 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -1.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.7 % |
| Return on Equity (ttm) | -18.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -2.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|